Central Nervous System Neoplasms

• 

  Subject Areas on Research

  • 18F-FDG PET/CT in primary central nervous system lymphoma in HIV-negative patients. 
  • A genetically modified allogeneic cellular vaccine generates MHC class I-restricted cytotoxic responses against tumor-associated antigens and protects against CNS tumors in vivo. 
  • A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. 
  • A phase I study of panobinostat in pediatric patients with refractory solid tumors, including CNS tumors. 
  • A review of VEGF/VEGFR-targeted therapeutics for recurrent glioblastoma. 
  • Activity of 9-dimethylaminomethyl-10-hydroxycamptothecin against pediatric and adult central nervous system tumor xenografts. 
  • Activity of temozolomide in the treatment of central nervous system tumor xenografts. 
  • Adrenal relapse of primary central nervous system diffuse large B-cell lymphoma: A case report. 
  • Adult infiltrating gliomas with WHO 2016 integrated diagnosis: additional prognostic roles of ATRX and TERT. 
  • Alex's Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007-2011. 
  • Altered telomeres in tumors with ATRX and DAXX mutations. 
  • American Brain Tumor Association Adolescent and Young Adult Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. 
  • An unusual presentation of chronic myelogenous leukemia: a review of isolated central nervous system relapse. 
  • Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. 
  • Antimetabolite therapy for lesser-risk B-lineage acute lymphoblastic leukemia of childhood: a report from Children's Oncology Group Study P9201. 
  • B-Cell Depletion Reduces the Maturation of Cerebral Cavernous Malformations in Murine Models. 
  • Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. 
  • Brain and other central nervous system tumor statistics, 2021. 
  • Breast cancer following spinal irradiation for a childhood cancer: A report from the Childhood Cancer Survivor Study. 
  • CBTRUS Statistical Report: Pediatric Brain Tumor Foundation Childhood and Adolescent Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. 
  • CBTRUS Statistical Report: Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2008-2012. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2009-2013. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2011-2015. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2012-2016. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2013-2017. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2014-2018. 
  • CBTRUS Statistical Report: Primary Brain and Other Central Nervous System Tumors Diagnosed in the United States in 2015-2019. 
  • CBTRUS statistical report: Primary brain and central nervous system tumors diagnosed in the United States in 2006-2010. 
  • CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2007-2011. 
  • Cancer in pregnancy: a review of the literature. Part I. 
  • Cell surface localization and density of the tumor-associated variant of the epidermal growth factor receptor, EGFRvIII. 
  • Cellular mechanisms of cyclophosphamide resistance: model studies in human medulloblastoma cell lines. 
  • Central Nervous System Cancers, Version 1.2015. 
  • Central Nervous System Cancers, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology. 
  • Central Nervous System Tumor Classification: An Update on the Integration of Tumor Genetics. 
  • Central Nervous System Tumors in Uganda: Outcomes of Surgical Treatment and Complications Assessed Through Telephone Survey. 
  • Central nervous system cancers, version 2.2014. Featured updates to the NCCN Guidelines. 
  • Central nervous system cancers. 
  • Central nervous system cancers. 
  • Central nervous system cancers. 
  • Central nervous system cancers: Clinical Practice Guidelines in Oncology. 
  • Central nervous system involvement by cutaneous T cell lymphoma. 
  • Central nervous system manifestations of marginal zone B-cell lymphoma. 
  • Central nervous system tumor distribution at a tertiary referral center in Uganda. 
  • Central nervous system. 
  • Changes in survival over time for primary brain and other CNS tumors in the United States, 2004-2017. 
  • Cilengitide with metronomic temozolomide, procarbazine, and standard radiotherapy in patients with glioblastoma and unmethylated MGMT gene promoter in ExCentric, an open-label phase II trial. 
  • Clinical and Genetic Risk Prediction of Subsequent CNS Tumors in Survivors of Childhood Cancer: A Report From the COG ALTE03N1 Study. 
  • Comparative integrated molecular analysis of intraocular medulloepitheliomas and central nervous system embryonal tumors with multilayered rosettes confirms that they are distinct nosologic entities. 
  • Completeness and concordancy of WHO grade assignment for brain and central nervous system tumors in the United States, 2004-2011. 
  • Completeness of required site-specific factors for brain and CNS tumors in the Surveillance, Epidemiology and End Results (SEER) 18 database (2004-2012, varying). 
  • Conditional survival after diagnosis with malignant brain and central nervous system tumor in the United States, 1995-2012. 
  • Conformal radiation therapy for childhood CNS tumors. 
  • Cyclophosphamide, doxorubicin, vincristine, and prednisone for primary central nervous system lymphoma: short-duration response and multifocal intracerebral recurrence preceding radiotherapy. 
  • Descriptive epidemiology of germ cell tumors of the central nervous system diagnosed in the United States from 2006 to 2015. 
  • Detection of glioma-associated gangliosides GM2, GD2, GD3, 3'-isoLM1 3',6'-isoLD1 in central nervous system tumors in vitro and in vivo using epitope-defined monoclonal antibodies. 
  • Different patterns of relapse associated with three intensive treatment regimens for pediatric E-rosette positive T-cell leukemia: a Pediatric Oncology Group study. 
  • Do race and age vary in non-malignant central nervous system tumor incidences in the United States? 
  • Dose intensive melphalan and cyclophosphamide with autologous hematopoietic stem cells for recurrent medulloblastoma or germinoma. 
  • Effect of imaging and catheter characteristics on clinical outcome for patients in the PRECISE study. 
  • Embryonal central nervous system neoplasms arising in infants and young children: a pediatric brain tumor consortium study. 
  • Epidemiology of Brain and Other CNS Tumors. 
  • Exceptional aggressiveness of cerebral cavernous malformation disease associated with PDCD10 mutations. 
  • Exomic sequencing of four rare central nervous system tumor types. 
  • Germline genetic landscape of pediatric central nervous system tumors. 
  • Glioblastoma multiforme: a review of where we have been and where we are going. 
  • Glioblastoma multiforme: an emerging paradigm of anti-VEGF therapy. 
  • Gliomatosis cerebri: cytologic and autopsy findings in a case involving the entire neuraxis. 
  • Glioneuronal tumors of the central nervous system. 
  • Global incidence of malignant brain and other central nervous system tumors by histology, 2003-2007. 
  • Global, regional, and national burden of brain and other CNS cancer, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016. 
  • HIV disorders of the brain: pathology and pathogenesis. 
  • Hematologic toxicity during craniospinal irradiation: the impact of prior chemotherapy. 
  • High-dose methotrexate for primary CNS lymphoma in the elderly. 
  • High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma. 
  • Immunohistochemistry of the glial fibrillary acidic protein: basic and applied considerations. 
  • Importance of the intersection of age and sex to understand variation in incidence and survival for primary malignant gliomas. 
  • Improved grading of IDH-mutated astrocytic gliomas. 
  • Incidence and survival trends for medulloblastomas in the United States from 2001 to 2013. 
  • Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202). 
  • Intensive chemotherapy with and without cranial radiation for Burkitt leukemia and lymphoma: final results of Cancer and Leukemia Group B Study 9251. 
  • Intracerebral Flexner-Wintersteiner Rosette-Rich Tumor With Somatic RB1 Mutation: A CNS Embryonal Tumor With Retinoblastic Differentiation. 
  • Invasiveness is associated with metastasis and decreased survival in hemangiopericytoma of the central nervous system. 
  • Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. 
  • Is There a Role for Immunotherapy in Central Nervous System Cancers? 
  • Is mortality due to primary malignant brain and other central nervous system tumors decreasing? 
  • Isolated Central Nervous System Chloroma as a Presenting Sign of Relapsed Pediatric Acute Lymphoblastic Leukemia. 
  • Lactotetraose series ganglioside 3',6'-isoLD1 in tumors of central nervous and other systems in vitro and in vivo. 
  • Lesions from patients with sporadic cerebral cavernous malformations harbor somatic mutations in the CCM genes: evidence for a common biochemical pathway for CCM pathogenesis. 
  • Longitudinal assessment of late-onset neurologic conditions in survivors of childhood central nervous system tumors: a Childhood Cancer Survivor Study report. 
  • Low-stage medulloblastoma: final analysis of trial comparing standard-dose with reduced-dose neuraxis irradiation. 
  • Molecular phenotype of simian virus 40 large T antigen-induced primitive neuroectodermal tumors in four different lines of transgenic mice. 
  • Mutant metabolic enzymes are at the origin of gliomas. 
  • NCCN Guidelines Insights: Central Nervous System Cancers, Version 1.2017. 
  • No free lunch: secondary neoplasms after stereotactic radiation. 
  • Noncutaneous malignant tumors in the PUVA follow-up study: 1975-1996. 
  • O6-benzylguanine-mediated enhancement of chemotherapy. 
  • O6-benzylguanine-mediated enhancement of nitrosourea activity in Mer- central nervous system tumor xenografts--implications for clinical trials. 
  • O6-methylguanine-DNA methyltransferase (MGMT) immunohistochemistry as a predictor of resistance to temozolomide in primary CNS lymphoma. 
  • PROMACE-MOPP and intrathecal chemotherapy for CNS lymphomas. 
  • Pan-PI3Ki targets multiple B-ALL microenvironment interactions that fuel systemic and CNS relapse. 
  • Partnership for defining the impact of 12 selected rare CNS tumors: a report from the CBTRUS and the NCI-CONNECT. 
  • Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. 
  • Pediatric Central Nervous System Tumors in Nepal: Retrospective Analysis and Literature Review of Low- and Middle-Income Countries. 
  • Phase 2 study of temozolomide in children and adolescents with recurrent central nervous system tumors: a report from the Children's Oncology Group. 
  • Phase 2 trial of erlotinib plus sirolimus in adults with recurrent glioblastoma. 
  • Phase I study of SU5416, a small molecule inhibitor of the vascular endothelial growth factor receptor (VEGFR) in refractory pediatric central nervous system tumors. 
  • Phase I study of intraventricular administration of rituximab in patients with recurrent CNS and intraocular lymphoma. 
  • Phase I trial of carmustine plus O6-benzylguanine for patients with recurrent or progressive malignant glioma. 
  • Phase II study of imatinib mesylate and hydroxyurea for recurrent grade III malignant gliomas. 
  • Phase III clinical evaluation of gadoteridol injection: experience in pediatric neuro-oncologic MR imaging. 
  • Pigmented Lesions of the Nervous System and the Neural Crest: Lessons From Embryology. 
  • Pilocytic astrocytoma: correlation between the initial imaging features and clinical aggressiveness. 
  • Pilocytic astrocytomas: where do they belong in cancer reporting? 
  • Preparing an oncolytic poliovirus recombinant for clinical application against glioblastoma multiforme. 
  • Primary CNS lymphoma in HIV positive and negative patients: comparison of clinical characteristics, outcome and prognostic factors. 
  • Primary central nervous system histiocytic sarcoma: A case report and review of literature. 
  • Primary central nervous system lymphoma in patients with and without HIV infection: a multicenter study and comparison with U.S national data. 
  • Primary central nervous system lymphoma with systemic metastasis: case report and review. 
  • Primary central nervous system lymphomas: a 30-year experience at a single institution. 
  • Promising survival and concomitant radiation plus temozolomide followed by adjuvant temozolomide. 
  • Recent advances in the treatment of malignant astrocytoma. 
  • Reply to M.C. Chamberlain. 
  • Risk assessment for developing gliomas: a comparison of two cytogenetic approaches. 
  • SEER insights. 
  • Safety and Diagnostic Efficacy of Gadobenate Dimeglumine in MRI of the Brain and Spine of Neonates and Infants. 
  • Second messenger systems in human gliomas. 
  • Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial. 
  • Single nucleotide polymorphisms of matrix metallopeptidase 3 and risk of gliomas in a Chinese Han population. 
  • Surgical neuropathology update: a review of changes introduced by the WHO classification of tumours of the central nervous system, 4th edition. 
  • Surveillance for subsequent neoplasms of the CNS for childhood, adolescent, and young adult cancer survivors: a systematic review and recommendations from the International Late Effects of Childhood Cancer Guideline Harmonization Group. 
  • Survivorship in adults with malignant brain and other central nervous system tumor from 2000-2014. 
  • Tagging SNPs in non-homologous end-joining pathway genes and risk of glioma. 
  • Template for Reporting Results of Biomarker Testing of Specimens From Patients With Tumors of the Central Nervous System. 
  • The CBTRUS story: providing accurate population-based statistics on brain and other central nervous system tumors for everyone. 
  • The Epidemiology of Central Nervous System Tumors. 
  • The Utility of Expert Diagnosis in Surgical Neuropathology: Analysis of Consultations Reviewed at 5 National Comprehensive Cancer Network Institutions. 
  • The current landscape of immunotherapy for pediatric brain tumors. 
  • The elderly left behind-changes in survival trends of primary central nervous system lymphoma over the past 4 decades. 
  • The potential of cerebrospinal fluid-based liquid biopsy approaches in CNS tumors. 
  • Topotecan for the treatment of recurrent or progressive central nervous system tumors - a pediatric oncology group phase II study. 
  • Transcriptome clarifies mechanisms of lesion genesis versus progression in models of Ccm3 cerebral cavernous malformations. 
  • Trastuzumab emtansine (T-DM1) versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer and central nervous system metastases: a retrospective, exploratory analysis in EMILIA. 
  • Treatment of newly diagnosed glioblastoma multiforme. 
  • Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010. 
  • Understanding the Revised Fourth Edition of the World Health Organization Classification of Tumours of the Central Nervous System (2016) for Clinical Decision-making: A Guide for Oncologists Managing Patients with Glioma. 
  • Utility of postmortem magnetic resonance imaging in clinical neuropathology. 
  • Viruses as therapeutic agents against malignant disease of the central nervous system. 
  • Viruses for the treatment of malignant glioma. 
  • Years of potential life lost for brain and CNS tumors relative to other cancers in adults in the United States, 2010. 
  • ZD6474, a novel tyrosine kinase inhibitor of vascular endothelial growth factor receptor and epidermal growth factor receptor, inhibits tumor growth of multiple nervous system tumors. 
• 

  Keywords of People

  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Yan, Hai, Adjunct Professor of Pathology, Pathology